The increasing concern of multidrug-resistant bacterial and fungal pathogens has raised an urgent need for more efficient and accurate drug discovery strategies. Conventional strategies are becoming less effective in addressing the increasing complexity of microbial resistance development. In this article, a quantum-assisted bioinformatics platform is introduced that integrates quantum computing, artificial intelligence (AI), explainable AI (xAI), and blockchain technology to simplify the identification of new anti-bacterial and anti-fungal organic compounds. Quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE), are utilised to model the accurate interactions between potential compounds and target microbial proteins. Machine learning models create and refine novel molecular structures, whereas xAI provides interpretability of predictions by identifying molecular features associated with activity and toxicity. High-throughput screening and in vivo assays confirm the efficacy, pharmacokinetics, and safety of the compound. An ongoing feedback loop refines compound structures based on real-world performance, and blockchain enables secure, tamper-proof collaboration between institutions. This interdisciplinary solution not only enhances the accuracy of predictions and shortens development time but also improves transparency, collaboration, and personalisation in the battle against antimicrobial resistance.
The increasing concern of multidrug-resistant bacterial and fungal pathogens has raised an urgent need for more efficient and accurate drug discovery strategies. Conventional strategies are becoming less effective in addressing the increasing complexity of microbial resistance development. In this article, a quantum-assisted bioinformatics platform is introduced that integrates quantum computing, artificial intelligence (AI), explainable AI (xAI), and blockchain technology to simplify the identification of new anti-bacterial and anti-fungal organic compounds. Quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE), are utilised to model the accurate interactions between potential compounds and target microbial proteins. Machine learning models create and refine novel molecular structures, whereas xAI provides interpretability of predictions by identifying molecular features associated with activity and toxicity. High-throughput screening and in vivo assays confirm the efficacy, pharmacokinetics, and safety of the compound. An ongoing feedback loop refines compound structures based on real-world performance, and blockchain enables secure, tamper-proof collaboration between institutions. This interdisciplinary solution not only enhances the accuracy of predictions and shortens development time but also improves transparency, collaboration, and personalisation in the battle against antimicrobial resistance.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
The integration of quantum computing and artificial intelligence (AI), collectively termed Quantum AI, is revolutionizing the pharmaceutical industry by reshaping the paradigms of drug discovery and development. Traditional approaches to drug design are often limited by high costs, extensive timelines, and the computational intractability of simulating complex molecular interactions. Quantum computing offers exponential processing power, enabling the accurate modeling of quantum-level chemical phenomena that classical computers struggle to handle. Concurrently, AI contributes by enhancing data interpretation, prediction of molecular behaviors, and pattern recognition across large biological datasets. Together, Quantum AI enables faster identification of drug candidates, improved simulation of drug-target interactions, and early prediction of pharmacokinetics and toxicity. Key quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and quantum-enhanced machine learning, have demonstrated potential to outperform conventional methods in quantum chemical calculations. Moreover, this synergy facilitates personalized medicine by integrating patient-specific data to optimize therapeutic outcomes. Despite current challenges related to hardware scalability, algorithm optimization, and ethical integration, the future trajectory of Quantum AI is poised to redefine pharmaceutical innovation. This review underscores the transformative capabilities of Quantum AI and its potential to usher in a new era of efficient, cost-effective, and precision-driven drug development.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.
Q-CureMatch is a quantum-assisted drug discovery platform that is used to quickly identify potential drugs. These drugs can be found using quantum algorithms in terms of their binding to a protein, which reduces the time needed for molecular docking experiments. In addition, deep learning helps in improving the accuracy given by statistical models, with the use of elements in personalized medicine, which helps to identify treatment suitable for each individual using their own genomic information. Also, using molecule structure , protein folding information, and response to drugs, itimproves the accuracy of the results. drug discovery, where an understanding of simulatedmolecules at the quantum level is needed . Even though the development of quantum computing machines is at a primitive level, hybrid methods using quantum-classical computing are becoming increasingly higher. The goal of this review paper is to examine current techniques using AI for drug discovery, investigate the latest research in quantum computing applied to molecular modeling, and review hybrid approaches that bridge both technologies. It also focuses on current drawbacks and future enhancements, by laying the ground for the design and implementation of the Q-CureMatch platform. Key Words: Machine learning, quantum computing, molecular docking, drug-discovery, compound screening
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI\\\'s predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning's role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug- receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual\\\'s genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions.